Caprion to Merge With Ecopia Bio and Divest Its Proteomics Business | GenomeWeb
NEW YORK (GenomeWeb News) — Caprion Pharmaceuticals and Ecopia Biosciences have agreed to merge to form a new company that is focused on drug development, and then sell off Caprion’s proteomics business, the companies said today.
 
The firms said they expect to divest Caprion’s CellCarta proteomics unit within a year, and then will solely pursue oncology and infectious disease therapeutics. The new company will have three clinical therapeutic programs nearing commercialization, the companies said.  
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.